Bayer and Iambic partner on AI-driven small molecule drug discovery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
June 22, 2026 8:00 AM EDTCollaboration focuses on small molecule discovery Bayer to leverage Iambics AI platform to address hard-to-drug targets Collaboration will strengthen Bayers research and development portfolio by harnessing AI to accelerate drug discovery
BERLIN & SAN DIEGO--(BUSINESS WIRE)-- Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambics AI-driven platform. The collaboration is focused on small molecule discovery.
The collaboration will leverage Iambics AI-driven drug discovery... More
